Generalized Anxiety Disorder (GAD) Clinical Trial
Official title:
Clinical, Neurophysiological and Neuroendocrine Effects of Aerobe Exercise in Generalized Anxiety Disorder (GAD)
This study investigate the effect of high-intense aerobe exercise training (HIT) on clinical and physiological parameters (anxiety, somatisation, cortisol, alpha amylase, "mismatch negativity", loudness dependence auditory evoked potentials) in patients with generalized anxiety disorder (GAD). Half of patients will receive HIT, while the other half will receive aerobe exercise of low intensity.
Generalized anxiety disorder (GAD) is a prevalent psychiatric condition and characterized by
worrying of several topics of the daily life as well as stress-induced somatic symptoms (e.g.
headache or musculoskeletal pain). Disturbed monoaminergic neurotransmission, changes in
central information processing and altered levels of stress markers were reported as to be
biological correlates of GAD or other stress-related disorders. Cognitive behavioral therapy
is the first-line treatment in GAD, but it seems to be less effective than in other anxiety
disorders. There is, however, some evidence for an anxiolytic activity of aerobe exercise. In
this context, different forms of aerobe training were found to be associated with significant
reduction of clinical symptoms in panic disorder, agoraphobia or social phobia as well as a
normalisation of some of its pathophysiological markers.
In this study, 20 patients with GAD will receive a high-intensive aerobe training (HIT, 6
HIT-sessions of 20 minutes within a period of 12 days). Additionally, 20 GAD-patients will
undergo a less intense aerobe training matched regarding frequency and duration of sessions.
Prior to the first training session, after completing the training (day 12) and 30 days after
baseline, symptoms of anxiety and somatisation will assessed by using established
questionnaires. Moreover, saliva samples and electroencephalogram (EEG) will performed at the
same times of assessment in order to evaluating changes of cortisol, alpha amylase, "mismatch
negativity" and loudness dependence auditory evoked potentials.
We hypothesize, that GAD-patients which undergo HIT, will show a stronger and more sustained
improvement of both, clinical symptoms and formally altered electrophysiological and
endocrinological parameters.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01470469 -
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
|
Phase 2 | |
Completed |
NCT02305797 -
EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
|
Phase 3 | |
Active, not recruiting |
NCT05738850 -
Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT06024239 -
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
|
Phase 1 | |
Withdrawn |
NCT02708472 -
Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation for the Treatment of Generalized Anxiety Disorder
|
N/A |